Company Filing History:
Years Active: 2021-2024
Title: Immanuel Lerner: Innovator in Neuroactive Compounds and Immunomodulation
Introduction
Immanuel Lerner is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of neuroactive pharmaceuticals and immunomodulation. With a total of 2 patents, Lerner's work focuses on innovative compounds that have the potential to impact various medical applications.
Latest Patents
Lerner's latest patents include groundbreaking inventions in the realm of GABA receptor modulation and TLR4 activation. The first patent, titled "Positive allosteric modulators of GABAreceptor," presents new GABA receptor-binding compounds that enhance the activation of GABA. These compounds are designed for use in neuroactive pharmaceutical compositions, improving sperm motility, and labeling biomolecules. The second patent, "Peptide agonists and antagonists of TLR4 activation," introduces a group of peptides that can activate or inhibit toll-like receptor 4 (TLR4). These peptides are valuable for modulating inflammatory signaling and host defense pathways, with applications in immunomodulatory compositions such as vaccine adjuvants.
Career Highlights
Lerner is associated with Pepticom Ltd., a company that focuses on peptide-based innovations. His work at Pepticom has allowed him to explore the therapeutic potential of peptides in various medical fields. His contributions have been instrumental in advancing the understanding of receptor modulation and its implications for drug development.
Collaborations
Throughout his career, Lerner has collaborated with notable colleagues, including Amit Michaeli and Anke Burger-Kentischer. These collaborations have fostered a dynamic research environment, leading to innovative solutions in the field of pharmaceuticals.
Conclusion
Immanuel Lerner's work exemplifies the intersection of innovation and medical science. His patents reflect a commitment to advancing therapeutic options through novel compounds. As he continues to explore new frontiers in neuroactive and immunomodulatory research, Lerner remains a key figure in the scientific community.